Immunocore Ltd has strengthened its board by appointing Laura Wade-Gery and Kristine Peterson as non-executive directors, the privately owned company announced on Thursday.
Laura Wade-Gery brings to the board over 20 years' executive experience in major publicly-listed companies. Her most recent position saw her serve as executive director at Marks & Spencer Group plc (LON: MKS), where she led the digital transformation of the business, resulting in online sales doubling.
She has also held numerous senior positions at Tesco plc (LON: TSCO), most notably CEO of the online business for seven years, and has been a member of the board of Trinity Mirror plc (LON: TNI). She is currently a non-executive director on the boards of the John Lewis Partnership and British Land plc (LON: BLND). She is also a member of the Government Digital Strategy Advisory Board.
Kristine Peterson has more than 30 years' experience in the global pharmaceutical and biotech industry, most recently serving as CEO for Valeritas Inc. Here she progressed the company to commercialisation and achieved US Food and Drug Administration (FDA) and European Medicines Agency (EMA) approval for its Type 2 diabetes drug device.
Her previous roles include company group chair at Johnson & Johnson (NYSE: JNJ) and president and SVP of commercial operations for Biovail Corporation. She also worked at Bristol-Myers Squibb (NYSE: BMY) for 20 years, holding several senior roles, including being responsible for its cardiovascular and metabolics business unit.
Peterson remains a member of other boards of directors for several pharmaceutical and biotech companies, including Amarin Corporation (NASDAQ: AMRN), Paratek Pharmaceuticals (NASAQ: PRTK), Enanta Pharmaceutics (NASDAQ: ENTA), pSivida (NASDAQ: PSDV) and ImmunoGen (NASDAQ: IMGN). She is also senior advisor to the Healthcare Businesswomen's Association and was a member of the Biotechnology Industry Organization Board.
Diamyd Medical granted US FDA Fast Track designation for Diamyd diabetes treatment
Aprecia names new chief commercial officer
Insulet's Omnipod 5 integration with Abbott FreeStyle Libre 2 Plus Sensor secures CE Mark approval
Kyowa Kirin enrols first subject in phase two tivozanib eye drops (KHK4951) clinical trial
Novo Nordisk to boost manufacturing capacity with acquisition of three fill-finish sites
Breye Therapeutics commences phase 1b/2a danegaptide clinical trial
DexCom Inc breaks ground on new manufacturing facility in Ireland
VibroSense Dynamics AB secures provisional patent for chemotherapy-induced nerve damage prediction
Innovent Biologics signs collaboration agreement with Sanegene Bio USA
Japan approves GSK's filing for Arexvy vaccination for at-risk adults
Arecor Therapeutics plc extends collaboration with Eli Lilly
OptiBiotix Health partners with Ravenswood for SlimBiome distribution in Australia and New Zealand
Boehringer Ingelheim granted European approval of oral liquid medication for feline diabetes